G-CSF receptor in progenitor mobilization

G-CSF 受体在祖细胞动员中的作用

基本信息

  • 批准号:
    7077018
  • 负责人:
  • 金额:
    $ 29.88万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-06-01 至 2009-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The long-range objective of this research is to characterize the mechanisms that regulate the mobilization of hematopoietic progenitor cells (HPC) from the bone marrow to blood. Hematopoietic stem cell transplantation is a potentially curative therapy for patients with advanced hematological malignancies. Recently, mobilized peripheral blood HPC instead of bone marrow-derived HPC have been used because of reduced engraftment times and relative ease of collection. Current mobilization protocols utilizing granulocyte colony stimulating factor (G-CSF) alone are generally well tolerated but not universally effective and are often associated with co-mobilization of neoplastic cells. A better understanding of the mechanisms that regulate HPC mobilization may lead to the design of novel mobilization strategies that overcome these problems. Accumulating evidence suggests that interactions between stromal derived factor-1 (SDF-1, CXCL12) and its cognate receptor, CXCR4, may play a key role in regulating HPC and neutrophil trafficking from the bone marrow. Loss-of-function models for SDF-1 and CXCR4 have established a critical role for these genes in the migration of HPC from the fetal liver to bone marrow. More recently, gain-of-function mutations of the CXCR4 gene have been implicated in the pathogenesis of WHIM syndrome, a syndrome manifested, in part, by impaired neutrophil trafficking from the bone marrow. We recently showed that G-CSF treatment results in a significant decrease in SDF-1alpha protein in the bone marrow of wild type mice. Finally, treatment with AMD3100, a selective antagonist of CXCR4, induces rapid and robust HPC mobilization in mice and humans. Collectively, these data suggest a hypothesis in which disruption of SDF-1/CXCR4 signaling is a key step in HPC mobilization by G-CSF. The objective of this research is to test this hypothesis and define mechanisms by which mobilizing agents regulate SDF-1/CXCR4 signaling. The following specific aims are proposed. 1. We will determine whether gain-of-function mutations of the CXCR4 gene found in patients with WHIM syndrome are sufficient to induce impaired HPC and neutrophil trafficking from the bone marrow. 2. We will identify the mechanisms by which G-CSF regulates SDF-1 expression in the bone marrow. 3. We will determine whether disruption of SDF-1/CXCR4 signaling is a common final pathway by which diverse mobilizing agents mediate HPC mobilization.
描述(申请人提供):这项研究的长期目标是描述从骨髓到血液的造血祖细胞(HPC)动员的调节机制。造血干细胞移植是治疗晚期血液系统恶性肿瘤的一种潜在的治疗方法。近年来,由于植入次数减少,采集相对容易,动员的外周血HPC取代了骨髓来源的HPC。目前单独使用粒细胞集落刺激因子(G-CSF)的动员方案通常耐受性良好,但并不是普遍有效,而且经常与肿瘤细胞的联合动员有关。更好地理解管理HPC动员的机制可能会导致设计新的动员战略来克服这些问题。 越来越多的证据表明,基质衍生因子-1(SDF-1,CXCL12)与其同源受体CXCR4之间的相互作用可能在调节HPC和中性粒细胞从骨髓中的运输中发挥关键作用。SDF-1和CXCR4的功能丧失模型已经为这些基因在HPC从胎肝迁移到骨髓的过程中发挥了关键作用。最近,CXCR4基因的功能获得突变被认为与突发奇想综合征的发病机制有关,这种综合征的部分表现是骨髓中性粒细胞运输受损。我们最近发现,G-CSF治疗导致野生型小鼠骨髓中SDF-1α蛋白显著减少。最后,用CXCR4的选择性拮抗剂AMD3100治疗,可以在小鼠和人类中诱导快速而有力的HPC动员。总之,这些数据提出了一种假说,即SDF-1/CXCR4信号的中断是G-CSF动员HPC的关键步骤。本研究的目的是验证这一假说,并确定动员剂调节SDF-1/CXCR4信号的机制。提出了以下具体目标。 1.我们将确定在突发综合征患者中发现的CXCR4基因功能获得突变是否足以诱导骨髓HPC和中性粒细胞运输受损。 2.明确G-CSF调节骨髓中SDF-1表达的机制。 3.我们将确定SDF-1/CXCR4信号通路的中断是否是不同动员剂介导HPC动员的共同最终途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Daniel C Link其他文献

Enhancing hematopoietic growth factor performance
增强造血生长因子性能
  • DOI:
    10.1038/nm.3022
  • 发表时间:
    2012-12-06
  • 期刊:
  • 影响因子:
    50.000
  • 作者:
    Yen-Michael S Hsu;Daniel C Link
  • 通讯作者:
    Daniel C Link

Daniel C Link的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Daniel C Link', 18)}}的其他基金

Identification of new genetic causes of congenital neutropenia
先天性中性粒细胞减少症新遗传原因的鉴定
  • 批准号:
    10621903
  • 财政年份:
    2020
  • 资助金额:
    $ 29.88万
  • 项目类别:
Identification of new genetic causes of congenital neutropenia
先天性中性粒细胞减少症新遗传原因的鉴定
  • 批准号:
    10159977
  • 财政年份:
    2020
  • 资助金额:
    $ 29.88万
  • 项目类别:
Identification of new genetic causes of congenital neutropenia
先天性中性粒细胞减少症新遗传原因的鉴定
  • 批准号:
    10399626
  • 财政年份:
    2020
  • 资助金额:
    $ 29.88万
  • 项目类别:
Single Cell Spatial Characterization of the Human Bone Marrow Microenvironment
人类骨髓微环境的单细胞空间表征
  • 批准号:
    10115110
  • 财政年份:
    2020
  • 资助金额:
    $ 29.88万
  • 项目类别:
Specialized Program Of Research Excellence (SPORE) in Leukemia.
白血病专业卓越研究计划 (SPORE)。
  • 批准号:
    10439617
  • 财政年份:
    2013
  • 资助金额:
    $ 29.88万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10439618
  • 财政年份:
    2013
  • 资助金额:
    $ 29.88万
  • 项目类别:
Specialized Program Of Research Excellence (SPORE) in Leukemia.
白血病专业卓越研究计划 (SPORE)。
  • 批准号:
    9756314
  • 财政年份:
    2013
  • 资助金额:
    $ 29.88万
  • 项目类别:
Specialized Program Of Research Excellence (SPORE) in Leukemia
白血病专业卓越研究计划 (SPORE)
  • 批准号:
    9307740
  • 财政年份:
    2013
  • 资助金额:
    $ 29.88万
  • 项目类别:
Specialized Program Of Research Excellence (SPORE) in Leukemia.
白血病专业卓越研究计划 (SPORE)。
  • 批准号:
    10194393
  • 财政年份:
    2013
  • 资助金额:
    $ 29.88万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10194394
  • 财政年份:
    2013
  • 资助金额:
    $ 29.88万
  • 项目类别:

相似海外基金

Prevention of age-related hearing loss using bone marrow transplantation
利用骨髓移植预防与年龄相关的听力损失
  • 批准号:
    23K08999
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A Novel Bone Marrow Transplantation Approach for Sickle Cell Disease Using Targeted Marrow Irradiation
使用靶向骨髓照射治疗镰状细胞病的新型骨髓移植方法
  • 批准号:
    10737358
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
Tuning tyrosine kinase signalling to improve haematopoietic stem cell expansion and bone marrow transplantation
调节酪氨酸激酶信号传导以改善造血干细胞扩增和骨髓移植
  • 批准号:
    2889841
  • 财政年份:
    2023
  • 资助金额:
    $ 29.88万
  • 项目类别:
    Studentship
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
  • 批准号:
    10722602
  • 财政年份:
    2022
  • 资助金额:
    $ 29.88万
  • 项目类别:
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
一项针对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者进行非亲缘供体骨髓移植与免疫抑制治疗比较的 III 期随机试验
  • 批准号:
    10368246
  • 财政年份:
    2022
  • 资助金额:
    $ 29.88万
  • 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
  • 批准号:
    10600143
  • 财政年份:
    2022
  • 资助金额:
    $ 29.88万
  • 项目类别:
1/2A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation with Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients with Severe Aplastic Anemia
1/2A III 期随机试验,比较无关供体骨髓移植与免疫抑制治疗对新诊断患有严重再生障碍性贫血的儿童和年轻成人患者的影响
  • 批准号:
    10370775
  • 财政年份:
    2022
  • 资助金额:
    $ 29.88万
  • 项目类别:
The mycobiota, bone marrow transplantation, and clinical outcomes
真菌群、骨髓移植和临床结果
  • 批准号:
    10303678
  • 财政年份:
    2021
  • 资助金额:
    $ 29.88万
  • 项目类别:
The mycobiota, bone marrow transplantation, and clinical outcomes
真菌群、骨髓移植和临床结果
  • 批准号:
    10415200
  • 财政年份:
    2021
  • 资助金额:
    $ 29.88万
  • 项目类别:
Bone Marrow Transplantation in Human Disease
骨髓移植治疗人类疾病
  • 批准号:
    10196999
  • 财政年份:
    2019
  • 资助金额:
    $ 29.88万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了